A polymer comprising units having the structure (I): ##STR00001##
wherein x is 2 or 3, wherein L is (CH.sub.2).sub.y, where y is an integer from 1 to 10, or wherein L is CH(CH.sub.3)CH.sub.2S(CH.sub.2).sub.z, where z is an integer from 1 to 5; wherein [Q] is absent or is a polymerised moiety consisting of units having the structure (II): ##STR00002##
wherein R is a hydrocarbyl group, or a hydrocarbyl group containing one or more heteroatoms, wherein R may be linear, branched or cyclic, saturated or unsaturated, and wherein R has from 1 to 30 carbon atoms; wherein [Q] either consists of identical units of structure (II), or wherein [Q] consists of more than one different units of structure (II), differing in group R; and wherein X is a halogen or another chain terminating group. The polymers may find use as additives in lubricating compositions where they provide friction improvement and wear reduction.

A polymer comprising units having the structure (I): ##STR00001##
wherein x is 2 or 3, wherein L is (CH.sub.2).sub.y, where y is an integer from 1 to 10, or wherein L is CH(CH.sub.3)CH.sub.2S(CH.sub.2).sub.z, where z is an integer from 1 to 5; wherein [Q] is absent or is a polymerised moiety consisting of units having the structure (II): ##STR00002##
wherein R is a hydrocarbyl group, or a hydrocarbyl group containing one or more heteroatoms, wherein R may be linear, branched or cyclic, saturated or unsaturated, and wherein R has from 1 to 30 carbon atoms; wherein [Q] either consists of identical units of structure (II), or wherein [Q] consists of more than one different units of structure (II), differing in group R; and wherein X is a halogen or another chain terminating group. The polymers may find use as additives in lubricating compositions where they provide friction improvement and wear reduction.

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

A solid-supported catalyst ligand which chelates palladium (II) species to form a complex that functions as a heterogeneous catalyst that is stable and can be recycled without significantly losing any catalytic activity in a variety of chemical transformations, a method for producing the solid-supported catalyst ligand and a method for catalyzing a palladium cross-coupling reaction, such as the Suzuki-Miyaura, Mizoroki-Heck, and Sonagashira reactions.

The present invention disclose a single step one pot process for synthesis of oxazoline and imidazole derivatives from glycerol using solid acid metal catalyst with improved yield.

The present invention disclose a single step one pot process for synthesis of oxazoline and imidazole derivatives from glycerol using solid acid metal catalyst with improved yield.

The present invention discloses a diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry of formula 3 and its synthesis method and application in an asymmetric catalytic reaction, wherein C.sub.2-symmetry is lost by introducing different groups into the diphenylamine backbone to realize precise control of “electronic effect” of the ligand backbone. An anthranilic acid derivative and an orthochlorobenzoic acid derivative are used as starting materials to prepare a compound of formula 1, and then the compound of formula 1 is reacted with a chiral amino alcohol compound to prepare a β-bishydroxy amide compound of formula 2, and the compound of formula 2 is further subjected to condensation to obtain the diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry of formula 3. The present invention also provides an application of a catalyst formed by coordination of the diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry with copper salt, zinc salt, nickel salt, iron salt or rhodium salt, in an asymmetric catalytic reaction.

##STR00001##

The present invention discloses a diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry of formula 3 and its synthesis method and application in an asymmetric catalytic reaction, wherein C.sub.2-symmetry is lost by introducing different groups into the diphenylamine backbone to realize precise control of “electronic effect” of the ligand backbone. An anthranilic acid derivative and an orthochlorobenzoic acid derivative are used as starting materials to prepare a compound of formula 1, and then the compound of formula 1 is reacted with a chiral amino alcohol compound to prepare a β-bishydroxy amide compound of formula 2, and the compound of formula 2 is further subjected to condensation to obtain the diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry of formula 3. The present invention also provides an application of a catalyst formed by coordination of the diphenylamine-linked chiral bis(oxazoline) ligand without C.sub.2-symmetry with copper salt, zinc salt, nickel salt, iron salt or rhodium salt, in an asymmetric catalytic reaction.

##STR00001##

This invention is directed to compounds of formula (I):

##STR00001##

where r, q, R, R.sup.2, R.sup.3, R.sup.4, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.7, R.sup.8, and R.sup.9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A.sub.4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.